Health Condition 1: N74- Female pelvic inflammatory disorders in diseases classified elsewhere
Conditions
Interventions
Intervention1: Chromium picolinate 100 MCG WITH D-chiro-Inositol 13.8 MG WITH Myo-inositol 550 MG WITH Vitamin D3 200 IU: Orally once daily after the meal
Control Intervention1: Not Applicable: Not Ap
Sponsors
Sun Pharma Laboratories Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Female subjects oligo menorrhea, amenorrhea with Polycystic ovarian syndrome (PCOS), aged 18 years to 40 years old and meet the following criteria: 2.Female subjects 18 years to 40 years (both inclusive) oligo menorrhea, amenorrhea with Polycystic ovarian syndrome (PCOS). 3.Subjects who are known cases of PCOS as per the Rotterdam Criteria, which requires presence of 2 of the following 3 conditions: -oligo/anovulation -hyperandrogenism- clinical (hirsutism or less commonly male pattern alopecia) or biochemical (raised free androgen index or free testosterone) -Polycystic ovaries on ultrasound (>=10 small antral follicles seen in each ovary) 4.Subjects with primary or secondary infertility (with PCOS as the apparent cause), and attempting to conceive at the time of signing ICF. 5.Patients with BMI between 18-29 kg/m2 (both inclusive) at the time of screening.
Exclusion criteria
Exclusion criteria: 1.Systemic diseases- Renal, hepatic cardiac, RS , frank DM, hypertension , congenital adrenal hyperplasia, ,hyperprolactinemia, acromegaly, functional hypothalamic amenorrhea. 2.Past H/O lactic acidosis. 3.Patients undergoing IV contrast media study or surgical procedures. 4.BMI ( >29 mg/) kg. 5.Any ovarian and/or abdominal abnormality interfering with ultrasound examination. 6.History / presence of undiagnosed vaginal bleeding. 7.History of clinically significant endocrine related abnormality . 8.Subject with history of abnormal thyroid function, congenital adrenal hyperplasia, or any other adrenal, pituitary, or ovarian condition that may be the cause of hyperandrogenism and/or anovulation. hyperprolactinemia, Addison and Cushing. 9.Subject in whom infertility is related to male factors, or female factors including uterine, tubal or cervical abnormality, primary/premature ovarian failure, pelvic infections, or adhesions etc. 10.Subject has received hormonal preparations, including oral/injectable contraceptive preparation in the past 6 months. 11.Subject is receiving drugs that can potentially influence ovulation, insulin resistance, and body weight (e.g. anti-epileptics, anti-psychotics, sulfonylureas, insulin sensitizers, corticosteroids, etc) within 5-half-lives prior to screening. Intermittent oral corticosteroids ( 12.Subject with history of or who test positive for Human Immunodeficiency Virus, Hepatitis B or Hepatitis C infection at screening. 13.Subject known to be allergic, hypersensitive, or intolerant to any of the contents of Normoz. 14.Subject who smokes or has stopped smoking within the last 3 months prior to screening. 15.Subject with history of alcohol or drug abuse within 6 months prior to screening. 16.Subject with history of epilepsy, thrombophilia, cardiovascular, gastrointestinal, hepatic, renal, pulmonary, auto-immune disease or any active infection, requiring treatment which at the investigatorâ??s discretion might interfere with the study. 17.Subject with history of malignancy. 18.Subject who has received an investigational product or has used an invasive investigational medical device within 30 days before the planned first dose of the study drug; or is currently enrolled in an investigational study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.To evaluate the regularization of Menses 2.To assess the Improvement in Ovulatory function 3.To assess the proportion of subjects achieving spontaneous ovulation at the end of 3 months. 4.To evaluate the normalization of Thyroid Profile 5.To evaluate the regularization of Menses 6.To assess the Improvement in Ovulatory function 7.To assess the proportion of subjects achieving spontaneous ovulation at the end of 3 months. 8.To evaluate the normalization of Thyroid Profile Timepoint: 1.Regularization of Menses measured by change from baseline to Month 6(3rd Month Interim). 2.Improvement in Ovulatory function measured by change from baseline to Month 6(3rd Month Interim). 3.Normalization of Thyroid Profile measured by change from baseline to Month 6(3rd Month Interim). 4.Proportion of subjects achieving spontaneous ovulation at the end of 3 months of treatment with Normoz. (0,3 months) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Improvement in clinical features of PCOS 2.change in oral glucose tolerance test 3.normalization of BMI. 4.change in Endocrine parameters in non-pregnant subjects 5.change in serum androgen levels in non-pregnant subjects 6.change in glycemic parameters in non-pregnant subjects 7.change in lipid parameters in non-pregnant subjects 8.Normalization of menstrual cycle in non-pregnant subjects 9.Clinical pregnancy rate 10.safety of D-CHIRO INOSITOL AND MYO-INOSITOL COMBINATIONTimepoint: 1.change from baseline to Month 6(3rd Month Interim). 2.change from baseline to Month 6(3rd Month Interim). 3.change from baseline to Month 6(3rd Month Interim). 4.baseline to 3 months of treatment with STUDY DRUG, in non-pregnant subjects. 5.baseline to 3 months of treatment with STUDY DRUG in non-pregnant subjects 6.baseline to 3 months of treatment with STUDY DRUG in non-pregnant subjects. 7.baseline to 3, 6 months of treatment with STUDY DRUG in non-pregnant subjects. | — |
Countries
India
Contacts
Public ContactDr Garima Kachhawa
All India institute of Medical sciences
Outcome results
None listed